Ibrutinib-Based Combination Therapy Exhibited Therapeutic Benefit In Newly Diagnosed Primary Central Nervous System Lymphoma.

Feili Chen,Diwen Pang,Hanguo Guo,Qiuxiang Ou,Xue Wu,Xinmiao Jiang,Xiaojuan Wei,Sichu Liu,Ling Huang,Zhanli Liang,Wenyu Li

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览8

暂无评分

摘要

2556Background: Ibrutinib has shown single-agent activity in relapse/refractory (R/R) primary central nervous system lymphoma (PCNSL), and the high dose methotrexate (HD-MTX) has been the backbone ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要